Drug Trial Radar · NCT01897831
Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
Last checked: Nov 20, 2026Latest source record: Jul 12, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Aug 2011
Primary completion
Aug 2015
Study completion Nov 2015
Sponsor
- Lead sponsor
- Xiangbei Welman Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 12, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In the proposed study, the investigators plan to evaluate the efficacy and safety of Piperacillin sodium and sulbactam sodium for injection (2:1) for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
Conditions
- Respiratory Tract Infections
- Urinary Tract Infections
Interventions
xin te mieDrug
durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- overall effectTime frame: two year
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.